相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients
Marzia Del Re et al.
PHARMACOLOGICAL RESEARCH (2021)
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Kevin Freeman-Cook et al.
CANCER CELL (2021)
Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity
Tyler Risom et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J. Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
Sunil Pancholi et al.
ONCOGENE (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
Kamal Pandey et al.
CANCERS (2020)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
Marc Hafner et al.
CELL CHEMICAL BIOLOGY (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells
Ahrum Min et al.
CANCER LETTERS (2018)
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Renee de Leeuw et al.
CLINICAL CANCER RESEARCH (2018)
The oncoprotein Myc controls the phosphorylation of S6 kinase and AKT through protein phosphatase 2A
Lidia Chellini et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer
Eric Haines et al.
Oncotarget (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer
Tian Du et al.
BREAST CANCER RESEARCH (2018)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Cristina Guarducci et al.
NPJ BREAST CANCER (2018)
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary roundtable discussion
Matthias Preusser et al.
ESMO OPEN (2018)
Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)
R. Finn et al.
ANNALS OF ONCOLOGY (2017)
Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Kelly K. Hunt et al.
CLINICAL CANCER RESEARCH (2017)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
Rekha Gyanchandani et al.
ONCOTARGET (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
Miriam Tarrado-Castellarnau et al.
MOLECULAR SYSTEMS BIOLOGY (2017)
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan et al.
NATURE COMMUNICATIONS (2017)
MYC Modulation around the CDK2/p27/SKP2 Axis
Per Hydbring et al.
GENES (2017)
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
S-U Woo et al.
ONCOGENESIS (2017)
A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
Shu-Fu Lin et al.
PLOS ONE (2017)
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Ami N. Shah et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Iman Doostan et al.
CLINICAL CANCER RESEARCH (2017)
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies
Adam M. Brufsky
CANCER TREATMENT REVIEWS (2017)
Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer
Cansu Karakas et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer
Carla L. Alves et al.
CLINICAL CANCER RESEARCH (2016)
Aromatase expression and regulation in breast and endometrial cancer
Hong Zhao et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
Sandeep Rajput et al.
ONCOTARGET (2016)
Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines
Esther P. Jane et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment
Todd VanArsdale et al.
CLINICAL CANCER RESEARCH (2015)
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)
Veronika Malinkova et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2015)
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
Stine Hole et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer
Zahi Mitri et al.
INVESTIGATIONAL NEW DRUGS (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Shaji K. Kumar et al.
BLOOD (2015)
Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy
D. Elias et al.
ONCOGENE (2015)
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
Monica M. Mita et al.
CLINICAL BREAST CANCER (2014)
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
Jorge Franco et al.
ONCOTARGET (2014)
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
Alexis B. Cortot et al.
CANCER RESEARCH (2013)
The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
Brijal M. Desai et al.
PLOS ONE (2013)
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
Andrea Cavazzoni et al.
CANCER LETTERS (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E
Said Akli et al.
CANCER RESEARCH (2011)
Phosphorylation Regulates c-Myc's Oncogenic Activity in the Mammary Gland
Xiaoyan Wang et al.
CANCER RESEARCH (2011)
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
Chellappagounder Thangavel et al.
ENDOCRINE-RELATED CANCER (2011)
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Todd W. Miller et al.
CANCER DISCOVERY (2011)
Intratumoral Estrogen Disposition in Breast Cancer
Ben P. Haynes et al.
CLINICAL CANCER RESEARCH (2010)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sensitivity to the Aromatase Inhibitor Letrozole Is Prolonged After a Break in Treatment
Gauri Sabnis et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Activation of the MEK-S6 Pathway in High-grade Ovarian Cancers
Aviva P. Ventura et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer
Anne E. Lykkesfeldt et al.
BMC CANCER (2009)
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
Matthew J. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
The discovery and mechanism of action of letrozole
Ajay S. Bhatnagar
BREAST CANCER RESEARCH AND TREATMENT (2007)
St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy
AU Buzdar
ANNALS OF ONCOLOGY (2006)
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
BJ Long et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression
SM Keenan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
An integrated view of aromatase and its inhibition
WR Miller et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2003)
The human CYP19 (aromatase P450) gene:: update on physiologic roles and genomic organization of promoters
SE Bulun et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2003)
Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation
CMW Chan et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways
BK Lundholt et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
R Sears et al.
GENES & DEVELOPMENT (2000)
分享论文
